These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Why hasn't neuroprotection worked in Parkinson's disease? Kieburtz K; Ravina B Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072 [No Abstract] [Full Text] [Related]
6. Neuroprotection in Parkinson's disease: an elusive goal. Biglan KM; Ravina B Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255 [TBL] [Abstract][Full Text] [Related]
7. Letter: Antiepileptogenic and neuroprotective effects of erythropoietin: recent data. Mikati MA; Mohler Cornett KM Epilepsia; 2009 Jun; 50(6):1654-5. PubMed ID: 19646143 [No Abstract] [Full Text] [Related]
8. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968 [No Abstract] [Full Text] [Related]
9. Neuroprotection in epilepsy: the Holy Grail of antiepileptogenic therapy. Sankar R Epilepsy Behav; 2005 Dec; 7 Suppl 3():S1-2. PubMed ID: 16243002 [No Abstract] [Full Text] [Related]
10. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
11. Re: Gout and risk of Parkinson disease: a prospective study. Schlesinger I; Schlesinger N Neurology; 2008 Jul; 71(1):70; author reply 70. PubMed ID: 18598007 [No Abstract] [Full Text] [Related]
12. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
13. Designing neuroprotection trials in Parkinson's disease. Kieburtz K Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102 [TBL] [Abstract][Full Text] [Related]
14. [The renewing drug therapy of epilepsy]. Keränen T; Kälviäinen R Duodecim; 1997; 113(18):1749-54. PubMed ID: 10892066 [No Abstract] [Full Text] [Related]
15. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Olanow CW Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316 [TBL] [Abstract][Full Text] [Related]
17. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106 [No Abstract] [Full Text] [Related]
18. [Treatments in the early stage of Parkinson disease]. Rascol O Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822 [No Abstract] [Full Text] [Related]
19. I can't get no satisfaction: still no neuroprotection for Parkinson disease. Ahlskog JE Neurology; 2007 Oct; 69(15):1476-7. PubMed ID: 17923609 [No Abstract] [Full Text] [Related]